Will Medicare cover the controversial Alzheimer’s drug?

Aduhelm: will medicare cover the controversial alzheimer's drug?

(HealthDay)—Following a months-long and unprecedented review, Medicare officials expect to announce within the next couple of weeks whether the program will cover the controversial Alzheimer’s drug Aduhelm. The drug’s benefits are in question and its annual price tag tops $28,000.

The U.S. Centers for Medicare and Medicaid Services (CMS) tend to cover with little fanfare most drugs approved by its sister agency, the U.S. Food and Drug Administration.

However, the FDA’s approval of Aduhelm (aducanumab) in June sparked a firestorm of criticism because showed no clear improvement in , plus a host of safety concerns.

Proponents such as the Alzheimer’s Association…

Read more…